215 related articles for article (PubMed ID: 31856443)
21. Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia.
Yoshida S; Onozawa M; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Hirabayashi S; Mori A; Hidaka D; Minauchi K; Shigematsu A; Hashiguchi J; Igarashi T; Kakinoki Y; Tsutsumi Y; Ibata M; Kobayashi H; Haseyama Y; Fujimoto K; Ishihara T; Sakai H; Ota S; Kondo T; Teshima T
Int J Hematol; 2023 Apr; 117(4):544-552. PubMed ID: 36572814
[TBL] [Abstract][Full Text] [Related]
22. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
23. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
Ren Y; Wang J; Zhang H; Mei C; Ye L; Luo Y; Zhou X; Zhu S; Jiang L; Wang L; Jin J; Tong H
Asia Pac J Clin Oncol; 2020 Jun; 16(3):172-179. PubMed ID: 32030889
[TBL] [Abstract][Full Text] [Related]
24. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
[TBL] [Abstract][Full Text] [Related]
25. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
26. The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions.
Bi X; French Z; Palmisiano N; Wen KY; Wilde L
Ann Hematol; 2022 Jun; 101(6):1251-1259. PubMed ID: 35288759
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen.
Lai B; Mu Q; Zhang Y; Chen Y; Yan X; Ouyang G
Hematology; 2021 Dec; 26(1):751-757. PubMed ID: 34555298
[TBL] [Abstract][Full Text] [Related]
28. TP53 mutations in older adults with acute myeloid leukemia.
Yanada M; Yamamoto Y; Iba S; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Mizuta S; Akatsuka Y; Okamoto M; Emi N
Int J Hematol; 2016 Apr; 103(4):429-35. PubMed ID: 26781615
[TBL] [Abstract][Full Text] [Related]
29. Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of
Middeke JM; Teipel R; Röllig C; Stasik S; Zebisch A; Sill H; Kramer M; Scholl S; Hochhaus A; Jost E; Brümmendorf TH; Naumann R; Steffen B; Serve H; Altmann H; Kunzmann V; Einsele H; Parmentier S; Schaich M; Burchert A; Neubauer A; Schliemann C; Berdel WE; Sockel K; Stölzel F; Platzbecker U; Ehninger G; Bornhäuser M; Schetelig J; Thiede C;
Leuk Lymphoma; 2021 Jun; 62(6):1432-1440. PubMed ID: 33399480
[TBL] [Abstract][Full Text] [Related]
30. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Duong VH; Ruppert AS; Mims AS; Borate U; Stein EM; Baer MR; Stock W; Kovacsovics T; Blum W; Arellano ML; Schiller GJ; Olin RL; Foran JM; Litzow MR; Lin TL; Patel PA; Foster MC; Redner RL; Al-Mansour Z; Cogle CR; Swords RT; Collins RH; Vergilio JA; Heerema NA; Rosenberg L; Yocum AO; Marcus S; Chen T; Druggan F; Stefanos M; Gana TJ; Shoben AB; Druker BJ; Burd A; Byrd JC; Levine RL; Boyiadzis MM
Cancer; 2023 Aug; 129(15):2308-2320. PubMed ID: 37078412
[TBL] [Abstract][Full Text] [Related]
31. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
33. Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT.
Najima Y; Sadato D; Harada Y; Oboki K; Hirama C; Toya T; Doki N; Haraguchi K; Yoshifuji K; Akiyama M; Inamoto K; Igarashi A; Kobayashi T; Kakihana K; Okuyama Y; Sakamaki H; Harada H; Ohashi K
Bone Marrow Transplant; 2021 Feb; 56(2):334-346. PubMed ID: 32760007
[TBL] [Abstract][Full Text] [Related]
34. [Clinical and prognostic values of TP53 mutation in patients with B-lineage acute lymphoblastic leukemia].
Du YY; Lyu KK; Xu MM; Yao WQ; Kang HZ; Han Y; Tang XW; Ma X; Wu XJ; He XF; Wu DP; Liu YJ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):396-401. PubMed ID: 34218582
[No Abstract] [Full Text] [Related]
35. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
[TBL] [Abstract][Full Text] [Related]
36. Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of
Liu H; Shi Y; Tao S; Li Y; Wang C; Yu L
Hematology; 2023 Dec; 28(1):2223866. PubMed ID: 37313982
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
[TBL] [Abstract][Full Text] [Related]
38. [Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation].
Jia WB; Liu JT; Yang XY; Wu HY; Wei YH; Can C; Wang RQ; He N; Gu CY; Ma DX; Ji CY
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):833-840. PubMed ID: 36709197
[No Abstract] [Full Text] [Related]
39. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
Ni J; Hong J; Long Z; Li Q; Xia R; Zeng Q
Int J Lab Hematol; 2020 Dec; 42(6):849-857. PubMed ID: 32730663
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.
Short NJ; Montalban-Bravo G; Hwang H; Ning J; Franquiz MJ; Kanagal-Shamanna R; Patel KP; DiNardo CD; Ravandi F; Garcia-Manero G; Takahashi K; Konopleva M; Daver N; Issa GC; Andreeff M; Kantarjian H; Kadia TM
Blood Adv; 2020 Nov; 4(22):5681-5689. PubMed ID: 33211826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
